Program Description & Educational Objectives

This CME activity is co-developed by Queen's University and PeerView Press.

This program has been peer reviewed by the Canadian Cardiovascular Society. The evidence presented has been found to be valid, objective, balanced and clinically relevant for physicians. The CCS recognizes the importance of this program and its objectives as it relates to cardiovascular health and care.

In this activity, Canadian physicians highlight current developments in stroke risk stratification in patients with atrial fibrillation, and discuss how both new and traditional anticoagulants can be used to prevent stroke in this at-risk population.

Upon completion of this activity, participants should be better able to:

• Understand the risks and benefits of various approaches to stroke prevention in patients with atrial fibrillation
• Apply the Canadian Cardiovascular Society Guidelines for risk stratification and stroke prevention in patients with atrial fibrillation

Target Audience

This activity has been designed to meet the educational needs of Canadian cardiologists, family practitioners, and internal medicine practitioners.

This activity is not intended for US physicians.

Accreditation

This event is an accredited group learning activity (section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University. (Maximum number of hours 0.25)

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Certificates of Completion are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: February 02, 2012 - February 01, 2013
Time to Complete: 15 minutes

Faculty & Disclosure / Conflict of Interest Policy

Queen's University has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

Planning Committee

Course Director and Interviewee
Paul Dorian, MD, MSc, FRCPC
University of Toronto
St. Michael's Hospital
Toronto, Ontario

Paul Dorian, MD, MSc, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant for Boehringer Ingelheim Ltd.; Bristol-Myers Squibb/Pfizer Inc.; sanofi-aventis; and Bayer Inc.
Grant/Research Support from Boehringer Ingelheim Ltd.; Bristol-Myers Squibb/Pfizer Inc.; and sanofi-aventis.
Advisory Board for Boehringer Ingelheim Ltd.; Bristol-Myers Squibb/Pfizer Inc.; sanofi-aventis; and Bayer Inc.

Christopher S. Simpson, MD, FRCPC, FACC, FHRS
Queen's University
Kingston General Hospital and Hotel Dieu Hospital
Kingston, Ontario

Christopher S. Simpson, MD, FRCPC, FACC, FHRS, currently has no financial interests/relationships or affiliations in relation to this activity.

Damian P. Redfearn, MD, MB, ChB, MRCPI
Queen's University
Kingston General Hospital
Kingston, Ontario

Damian P. Redfearn, MD, MB, ChB, MRCPI, currently has no financial interests/relationships or affiliations in relation to this activity.

Support

This activity is supported by an educational grant from Boehringer Ingelheim (Canada) Ltd./Ltée.

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.